Jordi Manera-Diaz

Central Parkway
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 231 publications

A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa.

A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa.

Journal: Journal of comparative effectiveness research

Published: July 15, 2026

MDBiomarkers: A queryable biomarkers database integrating multiple serum and tissue datasets for Duchenne muscular dystrophy.

MDBiomarkers: A queryable biomarkers database integrating multiple serum and tissue datasets for Duchenne muscular dystrophy.

Journal: Journal of neuromuscular diseases

Published: June 03, 2026

A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies.

A Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies.

Journal: International journal of molecular sciences

Published: May 20, 2026

Correction: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment.

Correction: Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment.

Journal: Cell death & disease

Published: May 18, 2026

Correction: Mesoangioblasts at 20: from the embryonic aorta to the patient bed.

Correction: Mesoangioblasts at 20: from the embryonic aorta to the patient bed.

Journal: Frontiers in genetics

Published: May 18, 2026

Correction: Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy.

Correction: Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy.

Journal: Cell death & disease

Published: April 17, 2026

Identification of prognostic biomarkers in a large cohort of patients with LGMD R2.

Identification of prognostic biomarkers in a large cohort of patients with LGMD R2.

Journal: Journal of neurology

Published: March 10, 2026

Visual mapping of muscle MRI fatty replacement patterns in genetic myopathies using dimensionality reduction.

Visual mapping of muscle MRI fatty replacement patterns in genetic myopathies using dimensionality reduction.

Journal: Neuromuscular disorders : NMD

Published: March 04, 2026

Quantitative tandem mass tag-based serum proteomics for longitudinal biomarker monitoring in Duchenne muscular dystrophy.

Quantitative tandem mass tag-based serum proteomics for longitudinal biomarker monitoring in Duchenne muscular dystrophy.

Journal: Clinical proteomics

Published: February 25, 2026

Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids.

Evaluation of a serum protein signature as monitoring biomarker for Duchenne muscular dystrophy in a long-term clinical trial with corticosteroids.

Journal: Skeletal muscle

Published: February 11, 2026

Evaluation of a serum protein signature as monitoring biomarker for Duchenne Muscular Dystrophy in a long-term clinical trial with corticosteroids.

Evaluation of a serum protein signature as monitoring biomarker for Duchenne Muscular Dystrophy in a long-term clinical trial with corticosteroids.

Journal: medRxiv : the preprint server for health sciences

Published: January 08, 2026

Exploring the impact of myotonia on daily functioning in myotonic dystrophy: a patient-reported survey.

Exploring the impact of myotonia on daily functioning in myotonic dystrophy: a patient-reported survey.

Journal: BMC neurology

Published: December 19, 2025

Showing 1-12 of 231

Last Updated: 09/26/2026